Cargando…

Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China

PURPOSE: To compare the efficacies and treatment outcomes of intravitreal anti-VEGF agents and laser therapy in retinopathy of prematurity (ROP). METHODS: A retrospective, non-randomized, comparative study of patients diagnosed with type 1 ROP or aggressive posterior ROP (A-ROP) treated with intravi...

Descripción completa

Detalles Bibliográficos
Autores principales: Linghu, Dandan, Cheng, Yong, Zhu, Xuemei, Deng, Xun, Yin, Hong, Jiang, Yanrong, Zhao, Mingwei, Li, Xiaoxin, Liang, Jianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193577/
https://www.ncbi.nlm.nih.gov/pubmed/35712119
http://dx.doi.org/10.3389/fmed.2022.911095
_version_ 1784726497435582464
author Linghu, Dandan
Cheng, Yong
Zhu, Xuemei
Deng, Xun
Yin, Hong
Jiang, Yanrong
Zhao, Mingwei
Li, Xiaoxin
Liang, Jianhong
author_facet Linghu, Dandan
Cheng, Yong
Zhu, Xuemei
Deng, Xun
Yin, Hong
Jiang, Yanrong
Zhao, Mingwei
Li, Xiaoxin
Liang, Jianhong
author_sort Linghu, Dandan
collection PubMed
description PURPOSE: To compare the efficacies and treatment outcomes of intravitreal anti-VEGF agents and laser therapy in retinopathy of prematurity (ROP). METHODS: A retrospective, non-randomized, comparative study of patients diagnosed with type 1 ROP or aggressive posterior ROP (A-ROP) treated with intravitreal anti-VEGF agents or laser therapy as primary treatment at the People's Hospital of Peking University. RESULTS: A total of 1,627 eyes of 862 patients were included. In Group 1, 399 eyes of 204 patients were diagnosed with A-ROP or zone I type 1 ROP. The initial regression of the anti-VEGF subgroup was better than that of the laser subgroup, and the reactivation rate and rate of progression to retinal detachment were lower than those of the laser subgroup. In Group 2, 1,228 eyes of 658 patients were diagnosed with zone II type 1 ROP. The reactivation rate of the laser subgroup was lower than that of the anti-VEGF subgroup. No significant differences were found in the initial regression and the probability of developing retinal detachment. Among the anti-VEGF agents, the reactivation rate in eyes treated with conbercept was much lower than that in eyes treated with ranibizumab. The spherical power and spherical equivalents of eyes treated with laser were significantly higher than those of eyes treated with anti-VEGF agents 1 year after initial treatment. CONCLUSIONS: In contrast to laser therapy, anti-VEGF agents as primary treatments have potential advantages for eyes with zone I type 1 ROP and A-ROP. For eyes with zone II type 1 ROP, laser photocoagulation and anti-VEGF agents therapy showed similar efficacy; however, the rate of reactivation with laser therapy was significantly lower than that with anti-VEGF agents. Among the anti-VEGF agents, the reactivation rate was much lower in eyes treated with conbercept than in eyes treated with ranibizumab. Compared to anti-VEGF agents, laser treated eyes had greater trend to myopia.
format Online
Article
Text
id pubmed-9193577
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91935772022-06-15 Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China Linghu, Dandan Cheng, Yong Zhu, Xuemei Deng, Xun Yin, Hong Jiang, Yanrong Zhao, Mingwei Li, Xiaoxin Liang, Jianhong Front Med (Lausanne) Medicine PURPOSE: To compare the efficacies and treatment outcomes of intravitreal anti-VEGF agents and laser therapy in retinopathy of prematurity (ROP). METHODS: A retrospective, non-randomized, comparative study of patients diagnosed with type 1 ROP or aggressive posterior ROP (A-ROP) treated with intravitreal anti-VEGF agents or laser therapy as primary treatment at the People's Hospital of Peking University. RESULTS: A total of 1,627 eyes of 862 patients were included. In Group 1, 399 eyes of 204 patients were diagnosed with A-ROP or zone I type 1 ROP. The initial regression of the anti-VEGF subgroup was better than that of the laser subgroup, and the reactivation rate and rate of progression to retinal detachment were lower than those of the laser subgroup. In Group 2, 1,228 eyes of 658 patients were diagnosed with zone II type 1 ROP. The reactivation rate of the laser subgroup was lower than that of the anti-VEGF subgroup. No significant differences were found in the initial regression and the probability of developing retinal detachment. Among the anti-VEGF agents, the reactivation rate in eyes treated with conbercept was much lower than that in eyes treated with ranibizumab. The spherical power and spherical equivalents of eyes treated with laser were significantly higher than those of eyes treated with anti-VEGF agents 1 year after initial treatment. CONCLUSIONS: In contrast to laser therapy, anti-VEGF agents as primary treatments have potential advantages for eyes with zone I type 1 ROP and A-ROP. For eyes with zone II type 1 ROP, laser photocoagulation and anti-VEGF agents therapy showed similar efficacy; however, the rate of reactivation with laser therapy was significantly lower than that with anti-VEGF agents. Among the anti-VEGF agents, the reactivation rate was much lower in eyes treated with conbercept than in eyes treated with ranibizumab. Compared to anti-VEGF agents, laser treated eyes had greater trend to myopia. Frontiers Media S.A. 2022-05-31 /pmc/articles/PMC9193577/ /pubmed/35712119 http://dx.doi.org/10.3389/fmed.2022.911095 Text en Copyright © 2022 Linghu, Cheng, Zhu, Deng, Yin, Jiang, Zhao, Li and Liang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Linghu, Dandan
Cheng, Yong
Zhu, Xuemei
Deng, Xun
Yin, Hong
Jiang, Yanrong
Zhao, Mingwei
Li, Xiaoxin
Liang, Jianhong
Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
title Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
title_full Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
title_fullStr Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
title_full_unstemmed Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
title_short Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
title_sort comparison of intravitreal anti-vegf agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in china
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193577/
https://www.ncbi.nlm.nih.gov/pubmed/35712119
http://dx.doi.org/10.3389/fmed.2022.911095
work_keys_str_mv AT linghudandan comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina
AT chengyong comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina
AT zhuxuemei comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina
AT dengxun comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina
AT yinhong comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina
AT jiangyanrong comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina
AT zhaomingwei comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina
AT lixiaoxin comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina
AT liangjianhong comparisonofintravitrealantivegfagentswithlaserphotocoagulationforretinopathyofprematurityof1627eyesinchina